Le Lézard
Classified in: Science and technology
Subject: Stock Sale/Buyback

Ciena Announces $250 Million Accelerated Share Repurchase Agreement

Ciena Corporation (NYSE: CIEN) (the "Company") today announced that it has entered into an accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. LLC ("Goldman") to repurchase $250.0 million of the Company's common stock as part of the Company's previously announced $1.0 billion share repurchase program. The Company expects to fund the ASR from cash on hand and cash generated from operations.

Under the ASR agreement, the Company will make a payment of $250.0 million to Goldman, and will receive an initial share delivery of approximately 2.7 million shares from Goldman, representing approximately 80% of the expected share repurchases under the ASR agreement, based on the closing price of the common stock of $74.12 on December 13, 2021. The final number of shares of common stock to ultimately be purchased by the Company under the ASR agreement will be based generally on the average of the daily volume-weighted average prices of the common stock during the term of the transaction, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement. Final settlement of the transactions under the ASR agreement is expected to occur during the fiscal quarter ending April 30, 2022.

About Ciena

Ciena (NYSE: CIEN) is a networking systems, services and software company. We provide solutions that help our customers create the Adaptive Networktm in response to the constantly changing demands of their end-users. By delivering best-in-class networking technology through high-touch consultative relationships, we build the world's most agile networks with automation, openness and scale. For updates on Ciena, follow us on Twitter @Ciena, LinkedIn, the Ciena Insights blog, or visit http://www.ciena.com/.

Note to Ciena Investors

You are encouraged to review the Investors section of our website, where we routinely post press releases, SEC filings, recent news, financial results, and other announcements. From time to time we exclusively post material information to this website along with other disclosure channels that we use. This press release contains certain forward-looking statements that are based on our current expectations, forecasts, information and assumptions, including statements about the expected completion date of the ASR and expected numbers of shares to be delivered under the ASR agreement. These statements involve inherent risks and uncertainties. Actual results or outcomes may differ materially from those stated or implied, because of risks and uncertainties, including that we cannot guarantee that share repurchases will enhance long-term stockholder value, and that share repurchases could increase the volatility of the price of our stock and diminish our cash reserves, and those risks and uncertainties detailed in our most recent annual and quarterly reports filed with the SEC. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies and can be identified by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. Ciena assumes no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

These press releases may also interest you

at 19:05
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the...

at 19:00
Smashing its records year by year, Lithuania's startup ecosystem has proved that there're no limits to growth. According to Dealroom.co, over the last five years, it has accelerated 16,6 times and is now valued at 10 billion EUR, placing Lithuania as...

at 18:53
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the opening of trading on Thursday, December 1: Nexstar Media Group Inc. (NASD:NXST) will replace Sabre Corp. (NASD:SABR) in the S&P...

at 18:46
DURECT Corporation , a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will...

at 18:45
ALZpath, Inc. announced today the launch of its first diagnostic assay for detection of phosphorylated tau 217...

at 18:30
Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, today announced that...

News published on 14 december 2021 at 09:05 and distributed by: